Metabolic Alkalosis

• FDA approval · 2026-01-12
  FDA Approved: ACETAZOLAMIDE — Supplemental Application (Ajanta Pharma USA Inc.)

  FDA approved Ajanta Pharma USA Inc.'s supplemental application for acetazolamide. This action approves changes to the product associated wit…

• FDA approval · 2023-08-16
  FDA Approved: ACETAZOLAMIDE — Supplemental Application (TRUPHARMA, LLC)

  FDA approved a supplemental application for acetazolamide from TRUPHARMA, LLC under ANDA 211372. This action updates the approval status of …

• FDA approval · 2021-02-22
  FDA Approved: ACETAZOLAMIDE — Original Application (TRUPHARMA, LLC)

  The FDA approved an original ANDA for Acetazolamide, a generic version manufactured by TRUPHARMA, LLC.

• FDA approval · 2016-10-27
  FDA Approved: ACETAZOLAMIDE — Original Application (Chartwell RX, LLC)

  FDA approved an original application for acetazolamide from Chartwell RX, LLC.

• CLINICAL_TRIALS trial_result · 2015-03-17
  Clinical Trial Update: Treatment of Metabolic Alkalosis With Acetazolamide. Effect on the Length of Mechanical Ventilation. [Phase 3]

  A Phase 3 clinical trial update examining acetazolamide for metabolic alkalosis and its effect on the length of mechanical ventilation in pa…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2014-01-20
  Clinical Trial Update: Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis [Phase 4]

  Phase 4 clinical trial evaluating acetazolamide for respiratory failure in the context of metabolic alkalosis has completed.

• CLINICAL_TRIALS trial_result · 2010-05-27
  Clinical Trial Update: Acetazolamide Facilitates Ventilator Weaning [NA]

  A clinical trial is investigating acetazolamide to facilitate ventilator weaning and treat metabolic alkalosis. The status of the trial is u…

• FDA approval · 2008-12-10
  FDA Approved: ACETAZOLAMIDE — Original Application (XGen Pharmaceuticals DJB, Inc.)

  FDA approves a generic acetazolamide product (Diamox) from XGen Pharmaceuticals DJB, Inc. under an Original Application.